Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

ams.

-- In its alliance with GlaxoSmithKline (GSK), Pharmacopeia reported that

it received a $500 thousand milestone payment for identification of a

compound for advancement into lead optimization six months ahead of the

original schedule. The compound is being evaluated as a potential

treatment for inflammatory pain. Pharmacopeia has already received $10

million from GSK for completion of early discovery activities and is

entitled to receive an additional $5 million payment upon the

completion of additional early discovery activities. Pharmacopeia is

also entitled to success-based milestone payments totaling up to $83

million per program for any drug development program pursued through

the multi-program alliance and up to double-digit royalties on the

sales of any product commercialized by GSK from the alliance.

Subsequent to the end of the third quarter:

Pharmacopeia announced that it has licensed a Phase 1 selective androgen receptor modulator (SARM) program from BMS, including lead and back-up compounds. Pharmacopeia plans to develop the lead compound from this program, PS178990, as a potential novel treatment for muscle wasting associated with a number of serious chronic and acute medical conditions such as surgical and severe burn recovery, end-stage renal disease and cancer- and AIDS-related cachexia. The SARM program has a broad portfolio of pending patent applications that, if granted, would provide intellectual property coverage to the SARM program through at least 2023. PS178990 has been well characterized by BMS both in pre-clinical studies and in a Phase 1 single ascending dose study. The company plans to conduct several Phase 1 studies in 2008, including a multiple ascending dose study of PS178990, to obtain additional safety and tolerability data before entering Phase 2.

In consideration for the SARM program license, Pharmacopei
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/22/2014)... 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced ... of common stock and warrants at a price of ... prior to deducting underwriting discounts and commissions and offering ... are immediately separable and will be issued separately.  The ... on The NASDAQ Stock Market under the ticker symbol ...
(Date:8/21/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... women,s health, has appointed Holly B. Bauzon ... Ms. Bauzon has a proven track record in ... laboratory services companies. She has more than 20 years ... she held the position of Director, Lab Services Sales ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... May 3 Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ) announced ... closes on Thursday, May 13, 2010 .  A conference call and live ... 5:00 p.m. Eastern Time to discuss the results. , ... To participate in the call, please dial 877-303-1298 (for ...
... EATONTOWN, N.J. , May 3 Osteotech, Inc. (Nasdaq: ... products for regenerative healing, announced today that the Company,s first quarter ... before the market opens on Monday, May 10, 2010 . ... webcast on Monday, May 10, 2010 , at 9:00 ...
Cached Medicine Technology:Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010 2Osteotech Announces First Quarter 2010 Financial Results Release and Conference Call 2
(Date:8/22/2014)... (PRWEB) August 22, 2014 Home ... of in-home care for seniors, is proud to announce ... Series. The upcoming webinar will feature Dr. Suzanne Steinbaum, ... Lenox Hill Hospital in New York City, National Spokesperson ... author. The webinar will cover the issues surrounding women ...
(Date:8/22/2014)... 22, 2014 (HealthDay News) -- Counseling may do little ... review finds. Researchers analyzed 66 studies that included ... were at high risk for drinking problems. Participants in ... participants in the rest of the studies attended group ... A counseling technique called motivational interviewing was used ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Inner city children have a higher-than-normal ... Researchers followed 516 inner city children in four U.S. cities ... birth until age 5 and found that at least 10 ... peanuts. Because only the three most common types of ... of inner city youngsters with food allergies may be even ...
(Date:8/22/2014)... few years, several breakthrough treatments have become available ... may benefit from these treatments can be pre-identified ... cancer. For example, patients whose lung cancer is ... significant benefit from the drug crizotinib, which targets ... attempting to replicate this success by matching different ...
(Date:8/22/2014)... severe disabilities and multiple chronic conditions are screened for ... or no chronic conditions, a new study has found. ... with moderate disabilities or women with only one chronic ... with the Li Ka Shing Knowledge Institute of St. ... often have other measures of social vulnerability, such as ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:Women with severe, chronic health issues are screened for breast cancer less often 2
... , TUESDAY, Aug. 16 (HealthDay News) -- For some ... of the disease who find standard treatments either intolerable ... relief. A new injectable treatment called pegloticase (brand ... patients, but researchers say that for the roughly ...
... Pneumonia kills more children around the world than any ... the causes of childhood pneumonia across many countries was ... study called the Pneumonia Etiology Research for Child Health ... 5 African and 2 Asian research sites coordinated by ...
... was a dramatic increase in the number of children,s flu-related hospital ... agency says. Over that time, flu rose from 65th to ... younger go to the hospital, according to a report from the ... found that skin infections rose from 13th to 7th in the ...
... Foundation launched a major new collaboration created with ... with its announcement that it will provide funding ... interventional radiology during 2012󈝹 in the Howard Hughes ... "The SIR Foundation, which seeks to further ...
... new study has shown the Flexible-Fiber CO2 laser to ... (TSC) without the,line of sight problems encountered with conventional ... Medical Center (BMC) and Boston University School of Medicine ... Neurosurgery . This is the first study to report ...
... for 15 minutes a day, or 92 minutes per week, ... who are inactive, according to a study published today in ... reduced deaths from any cause by 14 percent," said study ... The University of Texas MD Anderson Cancer Center Department of ...
Cached Medicine News:Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 2Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 3Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 4Health News:Largest global childhood pneumonia etiology study launched 2Health News:Largest global childhood pneumonia etiology study launched 3Health News:Society of Interventional Radiology Foundation funds Howard Hughes Medical Institute Award 2Health News:Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery 2Health News:Study finds 15 minutes of moderate daily exercise lengthens life 2Health News:Study finds 15 minutes of moderate daily exercise lengthens life 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: